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NOMENCLATURE 
 
Q-TAT  Quantitative Template Amplification Technology 
PCR   Polymerase Chain Reaction 
nDNA   Nuclear DNA 
mtDNA  Mitochondrial DNA 
cfDNA  cell-free DNA 
CRP   C - reactive protein 
ng   nanogram 
pg   picogram 
µl   Microliters 
DNA   Deoxyribonucleic Acid 
RFU   Relative Fluorescent Unit 
STR   Short Tandem Repeat 
SRY   region that determines sex on the Y chromosome 
Amelogenin   gene that determines sex 
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AMEL X  Amelogenin X 
AMEL Y  Amelogenin Y 
HPRT   hypoxanthine phosphoribosyl transferase 
Bp   base pair
1 
 
CHAPTER I 
 
 
INTRODUCTION 
 
Since the discovery of cell-free DNA floating in the plasma of all humans 
(Mandel, 1948), scientists have been trying to explain how DNA ends up liberated from 
cells into a soluble form and to find a diagnostic use for this occurrence. In the years 
since the discovery of cell-free DNA, there still has been no agreement on the pathway of 
DNA liberation. Scientists have proposed the following mechanisms underlying the 
presence of cell-free DNA in plasma: apoptosis, necrosis, terminal differentiation and 
active secretion (Lichtenstein, Melkonyan, Tomei, & Umansky, 2001). There are many 
arguments for and against each proposed mechanism for DNA liberation. 
While the exact method of DNA liberation is still unclear, the usefulness of cell-free 
DNA for diagnostic purposes has not remained in question. In recent years there have 
been many diagnostic uses for the levels of cell-free DNA in patient plasma. Increased 
levels of cell-free DNA in patients have been used to help diagnose different types of 
cancer (Sozzi et al., 2003). Another use for cell-free DNA is for genetic testing for 
unborn fetuses and other problems associated with pregnancy (Lo, 2000), due to the fact 
that fetal DNA is present in maternal plasma. 
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There have also been several studies linking the levels of cell-free DNA to 
different disease states that are associated with inflammation. High levels of cell-free 
DNA have been linked to physical over training (Fatouros et al., 2006) and to more 
serious conditions such as septic shock (Moreira, Prieto, Rodriguez, & Alvarez, 2010).” 
The studies by Fatouros et al. (2006) and Moreira et al (2010) compared levels of cell-
free DNA in normal healthy patients and in patients with known disease states, measured 
by currently accepted methods. 
In the study conducted by Fatouros et al. (2006), cell-free DNA (cf-DNA) was 
measured to identify a potential link between cfDNA and cell breakdown caused by 
overtraining. The study was conducted using 17 healthy males undergoing an 
increasingly strenuous exercise regimen. The experiment concluded that there was no 
correlation between cfDNA and the currently used clinical markers for inflammation and 
cell breakdown (CRP, Creatine Kinase, and Uric Acid). The authors did conclude that 
there was a connection between cfDNA and overtraining and that further study was 
warranted (Fatouros, et al., 2006).  
The study by Moreira et al. focused on cfDNA levels of patients with a varying 
degree of fever, ranging from localized infections to complete septic shock. The study 
was conducted using 110 patients who were diagnosed at the hospital with fever, and a 
control group. Patients were split into four groups based on their grade of fever/infection: 
1. Fever of unknown origin 
2. Localized infection 
3. Sepsis 
4. Septic Shock 
3 
 
The purpose of the study was to compare the usefulness of cfDNA as an indicator of the 
severity of infection as compared to C-Reactive Protein (CRP) and Procalcitonin (PCT) 
which are the currently used clinical indicators for inflammation. Not only did the authors 
conclude that there was a definite correlation between the level of sepsis and the level of 
cfDNA, the study showed that cfDNA was as good of indicator as PCT and better than 
CRP for monitoring sepsis (Moreira, et al., 2010). 
There are a few problems with the previously mentioned studies linking cell-free 
DNA to different inflammatory states. The Fatouros study was conducted with a smaller 
than optimal population. The second and larger problem is that both studies focused on 
only a few of the many known reasons for inflammation (overtraining and sepsis). 
Unfortunately, due to the common nature of inflammation, it is of very little diagnostic 
value without other indicators.  There are only a few different methods currently used to 
measure the amount of inflammation in sick patients, the most common being the 
Erythrocyte Sedimentation Rate and the level of C-reactive protein.  
The purpose of this study was to determine the link, if any, between the levels of 
cell-free DNA in patient plasma and their level of inflammation.  By measuring the levels 
of cell-free DNA in healthy patients and patients with elevated levels of C-reactive 
protein, which is known to be elevated in inflammation, any link between the 
concentration of cell-free DNA in patient plasma and the level of inflammation could be 
investigated. 
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CHAPTER II 
 
 
LITERATURE REVIEW 
HOW DNA BECOMES CELL-FREE: 
The location of DNA found in eukaryotes is in the nucleus of cells. In 1948, P. 
Mandel discovered that DNA also exists in human plasma (Mandel, 1948). The method 
of how, exactly, the DNA gets out of the cell and into the plasma of an individual is still a 
matter of scholarly debate.  Currently, four bodily processes are proposed to result in 
DNA ending up in the plasma of an individual: apoptosis, necrosis, active secretion and 
“terminal differentiation” (Lichtenstein, et al., 2001).  
 Apoptosis refers to the process that occurs when a cell reaches its designated 
lifespan and dies. Every day in the human body more than 1 trillion cells undergo 
mitosis. To maintain “tissue homeostasis”, approximately the same amount of cells must 
die each day (Lichtenstein, et al., 2001).  Usually in apoptosis, the DNA is cut into 
fragments. However, Lichtenstein noted that some DNA “escaped” from being 
fragmented and was present in the plasma in high molecular weight form.  
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The theory that apoptosis is the major contributor to the amount of cell-free DNA in 
plasma is contested in a more recent paper by Van der Vaart and Pretorius (2008). These 
authors, citing several studies dating as far back as the 1970s, make the claim that 
apoptosis is ‘not responsible for the free DNA observed in plasma’ (Van Der Vaart & 
Pretorius, 2008). Van der Vaart and Pretorius (2008) also make the argument that all 
apoptotic cells are ‘rapidly ingested’ by macrophages and that their DNA is digested by 
DNase II, found in lysosomes. They do concede; however, that some forms of apoptosis 
carried out by macrophages with impaired phagocytic function could cause some higher 
molecular weight DNA to escape. 
 Necrosis is another postulated mechanism for release of DNA into plasma and 
refers to cell death caused by injury.  Necrotic cells are dealt with in much the same way 
by the body as apoptotic cells. They are broken down and their DNA is often fragmented 
by proteases and nucleases.  Though it is possible that, as has been suggested for 
apoptotic cells, some DNA might escape, necrosis is not generally present in healthy 
individuals. Cell-free DNA is, however, found in both healthy (Mandel, 1948) and sick 
individuals (Moreira, et al., 2010). Both Lichtenstein et al., (Lichtenstein, et al., 2001) 
and Van der Vaart and Pretorius (2008), concede that it is not probable that necrosis is a 
significant source of cell-free DNA  
 Active secretion of DNA from living cells is yet another postulated mechanism 
for DNA to end up in the plasma.  An experiment in the 1970s brought to light evidence 
showing that lymphocytes release DNA until a “certain concentration was reached 
(Anker, Stroun, & Maurice, 1975)”. The experiment by Anker et al. (1975) was 
conducted by extracting 106 lymphocytes/ml from human blood and placing them in 
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sterile culture medium, and incubating them at 37⁰C for varying amounts of time. At 2 
hour, 4 hours, 6 hours and 8 hours the lymphocyte suspension was centrifuged and 25ml 
of the supernatant was removed to be tested for DNA concentration. The remaining 
lymphocyte suspension was then re-suspended in 25ml of fresh medium. DNA was then 
quantified in the harvested medium and found to contain an average of 22-23µg/culture. 
The authors maintain that active DNA secretion is the best explanation for the cell-free 
DNA, as once the concentration of 22-23µg/culture was reached it didn’t continue to 
increase. Also of note was that even with cells dying the concentration of cfDNA didn’t 
increase. However, the exact nature of this secretion of DNA was not fully explained by 
Anker et al (1975).  Due to the limited understanding of how lymphocytes secrete DNA, 
scientists are reluctant to accept active secretion as the mechanism underlying cell-free 
DNA.  
 The last source of cell-free DNA proposed is terminal differentiation. Terminal 
differentiation refers to cells, like red blood cells, losing their nuclei as part of the final 
stage in their maturation. Usually the nuclei of these cells are digested in much the same 
way as cells undergoing apoptosis.   Like all the other theories of how DNA ends up in 
plasma, lots of investigators contend that terminal differentiation does not play a 
significant role in the amount of DNA found in plasma. Those against terminal 
differentiation as a source of cell-free DNA cite the lack of differentiation in tumors. 
Often, individuals with cancer will have a significantly higher amount of cell-free DNA 
in their plasma. 
 Even though the pathway is not entirely understood as to how DNA is liberated 
from the nuclei of cells, cell free DNA can still be useful. Just as the principle of 
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inheritance was demonstrated by Mendel and his pea plants but not completely 
understood until many decades later, the fact that nuclear DNA ends up in plasma is 
useful even though there is not a clear understanding of how it got there. 
Diagnostic uses for cell-free DNA: 
Cancer Detection: 
 One of the great health concerns of the last few decades is cancer. Cancer comes 
in many forms and is frequently fatal. Many forms of cancer are, if they are found early 
enough, very treatable and show excellent recovery rates. The key to lowering the 
mortality rate for these types of cancer is early detection. Sozzi et al (2003). showed that 
the levels of cell-free DNA in plasma in patients with certain types of cancer are greatly 
increased (Sozzi, et al., 2003). Sozzi et al. (2003) demonstrated an average of eight times 
the level of cell-free DNA was present in patients with certain types of lung cancer as 
compared to control individuals, known to be heavy smokers but without cancer. The 
Sozzi et.al. study (2003) not only showed a correlation between cell-free DNA levels and 
lung cancer but also demonstrated a dramatic reduction in the amount of cell-free DNA in 
response to therapeutic treatment.  Quantifying the amount of cell-free DNA in those 
suspected of having cancer, especially those at high risk of certain types of cancer, offers 
a less invasive test that may be informative in the earliest stages of cancer. 
Fetal DNA detection: 
 An ever-present question in prenatal testing is how to develop tests that are less 
invasive and ultimately safer for both mother and child. The use of cell-free DNA from 
the fetus, present in maternal plasma, has been instrumental for the diagnosis of some 
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pre-natal conditions.  Y.M. Dennis Lo (Lo, 2000) stated that testing the fetal DNA in 
maternal plasma can be used for, ‘the prenatal diagnosis of fetal rhesus D status, sex-
linked disorders, and other paternally inherited genetic disorders. Abnormal fetal DNA 
concentrations in maternal plasma and serum have been found in common pregnancy-
associated disorders, including preterm labor and preeclampsia, as well as in pregnancies 
complicated by fetal trisomy 21 (Lo, 2000)’. As sampling cells from a fetus in utero 
carries a risk, testing of the mother’s plasma for cell-free DNA originating from the fetus 
is very advantageous.  
Inflammation: 
 One of the most widespread symptoms accompanying illness is inflammation. 
Inflammation can be caused by a multitude of problems ranging from overly intense 
physical training (Fatouros, et al., 2006), to life threatening conditions such as sepsis or 
septic shock (Moreira, et al., 2010).  Because of the wide ranging implications of 
inflammation, the need to distinguish between the causes quickly and accurately is very 
important. Bacterial cultures, though the gold standard to determine the identity of the 
organism causing sepsis, are slow. Cultures often take days to grow in culture medium. 
C-reactive protein, a marker of inflammation without infection, and Procalcitonin which 
is associated with inflammation occurring as a result of infection, are currently the 
methods used to detect inflammation and investigate its source. The quantification of 
cell-free DNA was shown to differentiate between localized inflammation and septic 
shock, with levels increasing “proportional to the severity of the infection (higher 
increases in sepsis than in localized infections, and in septic shock than in sepsis)” 
(Moreira, et al., 2010). Moreira et al. (2010), also demonstrated that the levels of cell-free 
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DNA were a better predictor than C-reactive protein and at least on the same level as the 
procalcitonin in measuring the level of infection. 
C-REACTIVE PROTEIN 
Overview: 
 C - reactive protein (CRP) is an ‘acute phase reactant’ found in the serum of 
humans and other species. It was first discovered in the 1930’s by William S. Tillett and 
Thomas Francis in their paper SEROLOGICAL REACTIONS IN PNEUMONIA WITH A 
NON-PROTEIN SOMATIC FRACTION OF PNEUMOCOCCUS (Tillett & Francis, 
1930).  It wasn’t until much later in the 1990s that it was realized that CRP was an 
excellent non-specific indicator of inflammation. It is thought to be more specific than 
other methods to measure inflammation such as the erythrocyte sedimentation rate (ESR). 
CRP is produced in the hepatocytes of the liver and has a half-life in the plasma of 
approximately 19 hours (Pepys & Hirschfield, 2003). 
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Structure: 
 CRP is a pentatrexin; it is one of two ‘calcium dependent 
ligand-binding plasma proteins’ (Pepys & Hirschfield, 2003). CRP has a pentameric 
structure consisting of five identical sub units, shown in the figure below. 
 
Figure 1. Two computer renderings of the structure of CRP. (Thompson, Pepys, & 
Wood, 1999) 
 
Clinical Findings and Significance: 
 While there is no standardized set of methodologies used in all laboratories to 
quantify CRP, the most commonly accepted unit of measure in the clinical laboratory is 
in mg/dL. The normal range of CRP circulating in the blood at any given time in a 
healthy individual should fall below 1.0 mg/dL. It should be noted; however, that normal 
ranges do tend to fluctuate slightly, depending on the testing population and the testing 
method employed. 
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Cell Free DNA Quantitation 
 With all the possible diagnostic uses of cell-free DNA the focus of this study was 
to analyze the correlation (if any) between the levels of cell-free DNA and levels of 
inflammation as measured by CRP levels. Using the Q-TAT method of DNA 
quantification, developed by Dr. Allen and various others at Oklahoma State University 
Center for Health Sciences (OSU-CHS), the concentration of cf-DNA (both nuclear and 
mitochondrial DNA) was measured in samples of a control group and our test group with 
known C-reactive protein levels. The cf-DNA could then be compared with the CRP 
level, to determine if a correlation indeed existed.  
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CHAPTER III 
 
 
METHODS 
 
The purpose of this study was to determine if there is a link between the levels of 
cell-free DNA in patient plasma and their state of inflammation as reflected in CRP level.  
This correlation, or lack thereof, can be shown by measuring the levels of cell-free DNA 
in healthy patients and patients with elevated levels of C-reactive protein, the indicator 
chosen to reflect the degree of inflammation present. 
I. Subjects/Participants 
 For the study, de-identified samples were taken from a control “healthy” 
population. The control population consisted of the plasma obtained from approximately 
100 small segments from units of donated blood obtained from the Memorial Blood 
Centers of Minnesota. Blood donors are required to be relatively healthy on the day of the 
donation to be eligible to give blood, making them suitable candidates to use as a 
baseline. Generally, this screening is accomplished by giving all donors an extensive 
questionnaire about their medical history and general health status on the day of donation.  
Patients that have been sick recently, that have certain chronic diseases, or that are “high 
risk” to have life threatening diseases are not allowed to donate.
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The experimental population consisted of 77 plasma/serum samples obtained 
from Regional Medical Laboratory in Tulsa, Oklahoma. These samples all had the level 
of C-reactive protein in their serum/plasma tested by Regional Medical Laboratory on the 
OLYMPUS 5400 clinical chemistry analyzer (Beckman Coulter, Brea, CA). The 
OLYMPUS 5400 measures CRP by photo-turbidimetry, or the change in light that is 
scattered as CRP complexes with reactants in the test and then compares results from 
unknown with a known calibration curve. The level of C-reactive protein in this group 
varied from a range of CRP levels that were clinically normal (≈50%) and levels above 
the diagnostic threshold and ranging to extremely high levels (≈50%).  
 
II. QTAT--Quantitative Template Amplification Technology 
Background: 
Dr. Robert Allen and various graduate students developed the Quantitative 
Template Amplification Technology (Q-TAT) Assay at OSU-CHS. The Q-TAT 
methodology was developed to cost effectively quantitate DNA in a given sample. Q-
TAT is currently being used by the Tulsa Police Department to quantitate their DNA 
samples. The Q-TAT assay was originally published in 2006 in the Journal of Forensic 
Science (Wilson, 2006). Q-TAT is a cost effective alternative to other DNA quantitation 
methods for several reasons, including the fact the assay is compatible with existing 
instrumentation present in the DNA typing laboratory.  
 Subsequent enhancements to the Q-TAT assay have included adding primers that 
will quantify and characterize mitochondrial DNA (Vandegrift, 2010) and use of the 
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assay to characterize the integrity of both nuclear and mitochondrial DNA recovered 
from biological samples (Vandegrift 2010 and Smith, 2011). The primer sequences for 
the Q-TAT assay can be found in TABLE 1 below. The change of fluorescent dye from 
ROX to NED was made to facilitate the use of Q-TAT on multi-capillary electrophoresis 
instruments such as the ABI 3130XL. 
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Primer 
Name 
Forward Sequence Reverse Sequence Fluorescent 
Label 
Product 
Size 
AMEL 5’ – ACC TCA TCC 
TGG GCA CCC TGG 
– 3’ 
5’ – AGG CTT GAG 
GCC AAC CAT 
CAG – 3’ 
6-FAM AMEL-X: 
210 bp  
AMEL-Y: 
216 bp 
 
SRY 5’ – ACG AAA GCC 
ACA CAC TCA AGA 
AT – 3’ 
5’ – CTA CAG CTT 
TGT CCA GTG GC 
– 3’ 
6-FAM 110 bp 
HPRT 5’ – TTA GTG AAA 
CTG GAA AAG CAA 
– 3’ 
5’ – TGA TAA TTT 
TAC TGG CGA 
TGT –3’ 
6-FAM 99 bp 
Primer 
Name 
Forward Sequence Reverse Sequence Fluorescent 
Label 
Product 
Size 
mt97 5’ – AGC TCT CCA 
TGC ATT TGG –3’ 
5’ – AGA CAG ATA 
CTG CGA CAT A – 
3’ 
NED 97 bp 
mt287 5’ – CAC CAT GAA 
TAT TGT ACG GT –
3’ 
5’ – CAA GGG ACC 
CCT ATC TGA –3’ 
NED 287 bp 
pRL 5’ – AAG GTG GTA 
AAC CTG ACG TTG 
– 3’ 
5’ – TTC ATC AGG 
TGC ATC TTC TTG 
– 3’ 
6-FAM 200 bp 
 
Table 1. The 5 Q-TAT primers, their forward and reverse sequences, the fluorescent 
dye used to identify them in the capillary electrophoresis instrument and their size 
in base pairs. 
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 Quantitation using Q-TAT relies on comparing fluorescence in PCR products 
amplified from samples with unknown quantities of DNA to that in PCR products 
produced from intact genomic DNA of known concentration (Allen and Fuller, 2006, 
Wilson et.al. 2010, Vandegrift 2010).  The DNA sample used to produce the standard 
curve contains DNA at 100ng/µl. This sample is serially diluted two fold to 31. 25 pg/ul 
and then the series of diluted samples (31.25-1000 pg) is amplified with the Q-TAT assay 
and products are analyzed using an ABI 3130XL genetic analyzer (Applied Biosystems, 
Inc., Foster City, CA).  
After being subjected to 30 rounds of PCR, one microliter aliquots of amplicon 
from each sample was placed on the ABI 3130XL genetic analyzer. Products were 
separated by size electrophoretically and fluorescence was quantified in each product. 
The ABI 3130XL produces electropherograms of the data as seen in FIGURE 2. 
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Figure 2.  An electropherogram produced by the ABI 3130XL for a standard sample 
known to contain 500 pg/µl of DNA. The four circled boxes are the markers used to 
construct the standard curve for total DNA (alX+alY in pg/µl), male DNA (SRY in 
pg/µl), and mtDNA (mt297 in cell equivalents). 
 
Each peak seen on the electropherogram represents a specific PCR product 
amplified from a genomic DNA target. The four targets that are circled (X, Y, mt287 and 
SRY) are of the most importance, while HPX and mt97 are included to show the possible 
presence of degraded DNA. The pRL peak is an internal control used in Q-TAT. pRL is a 
commercially available recombinant plasmid harboring the luciferase gene from Renilla 
rentiformis, otherwise known as the sea pansy. The pRL plasmid is used to confirm the 
lack of PCR inhibitors as it is extremely sensitive and will only amplify in the absence of 
inhibitors. 
Each amplicon seen in the electropherogram is labeled with several data:  the 
identity of the amplicon (the locus is preceded by the abbreviation “al”), the size of the 
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amplicon is given in base pairs, the peak height of fluorescence in a peak (in relative 
fluorescence units, or RFU), and the area of fluorescence under the peak are all shown. 
To construct the standard curve, the area of fluorescence contained within each peak was 
used as it is a more stable indicator than is the peak height. The area of RFU for each 
amplicon in a run can be plotted for each dilution of standard DNA.  The standard curve 
used for this study represented the average fluorescence at each dilution of DNA from 13 
different runs.  Separate standard curves were prepared for total human DNA (using 
amelogenin X + Y fluorescence), male DNA (using SRY fluorescence), and 
mitochondrial DNA (mtDNA) (using mt297 fluorescence) (FIGURE 3).  
The most important standard curve is for total nDNA. This standard curve is 
obtained by adding together the area of the Amelogenin X and Y targets. A standard 
curve can also be constructed for mtDNA. However, as no set of standardized 
concentration of pure mtDNA is readily available for use producing a standard curve, and 
mtDNA only makes up approximately .002% of all DNA extracted from a human cell 
(Vandegrift, 2010) the standard curve for mtDNA is constructed using cellular 
equivalents (CE). Each cellular equivalent of mtDNA equals the amount of mt287 
amplicon produced from 6 pg of input genomic DNA recovered from blood (Vandegrift, 
2010). The total DNA in a given sample is obtained by comparing the RFU of the sample 
to the Amel. X+Y standard curve, to produce the amount of nDNA in pg. The mt287 
cellular equivalents are determined by using that same number and dividing by six. 
FIGURE 3 and TABLES 2 are examples of the data needed for the construction of a 
standard curve and the standard curves themselves:  
 Figure 3. Standard curves for Amel X+Y, SRY, and mtDNA. Each standard curve 
was obtained from the averaging of 13 separate runs
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DNA (pg) Average X+Y mt287 CE Ave. SRY 
1000 43553.53846 184.3593284 56517.38462 
500 24163.30769 87.869816 22166.69231 
250 15220 61.00246333 15016.92308 
125 8565.230769 30.56684747 7703.307692 
62.5 4076.076923 13.23359731 3454.615385 
31.25 1620.538462 5.706186207 1982.846154 
0 196.5384615 0 769.6153846 
Table 2.  The average RFU values for 13 separate runs on the ABI 3130 genetic 
analyzer.  
 
 The Q-TAT assay includes multiple genomic DNA targets enabling total, male, 
and mitochondrial DNA to be quantified in a single PCR reaction.  The Q-TAT assay 
also incorporates primer sets that amplify products of differing size.  Recent work by 
Smith (2011) has demonstrated that the assay not only quantifies the different types of 
DNA in a sample, but the ratio of fluorescence contained within large versus small 
amplicon products from a given genomic DNA sample is a useful indicator of the degree 
of integrity of the DNA template recovered.  Thus, in a sample in which the ratio of 
fluorescence in SRY or HPT amplicons versus Amel-X + Amel Y differs significantly 
from a value of about 1.5 (SMITH 2011) demonstrated evidence of DNA degradation. 
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III. DNA Preparation 
 Plasma from healthy individuals and from those whose CRP levels were known 
was aliquoted into 100ul samples. DNA was recovered from these samples by mixing 
plasma with an equal volume of DNA extraction buffer composed of 40µl of Proteinase 
K (20 mg/ml in 10mM Tris-Cl, pH8.0 + 0.2M KCl and 10% glycerol), 50 µl of SDS 
(20% w/v in water) and 910µl of TNE (10mM Tris-Cl pH8.0 + 0.2M NaCl and 0.1 mM 
EDTA). This digestion buffer promotes the digestion of any leftover cellular components 
in the plasma/serum that would compromise DNA retrieval.  Samples were then mixed 
by vortex mixer for 1-2 seconds and placed in a 65⁰C heat block for two hours.  
IV. Extraction 
Once digestion was complete, an equal volume (200µl) of a 9:1 mixture of phenol 
to chloroform/isoamyl alcohol (24:1) was added and the samples were extracted by 
vortex mixing to create an emulsion. The samples were then centrifuged at 10,000 rpm 
for 1 minute in a microfuge to separate the aqueous and organic phases. The aqueous top 
phase containing the DNA was then transferred to a new microfuge tube.  300µl of 
chloroform/isoamyl alcohol mix was the added to the sample and again vortex mixed 
until cloudy.  The samples were centrifuged again at 10,000 rpm again for 1 minute to 
separate the phases. The aqueous (top) phase is again placed into a new tube before 
recovery of the DNA occurs. 
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V. DNA recovery by binding to silica.  
Final recovery of clean genomic DNA was accomplished using a ZYMO brand 
cleaner/concentrator kit (ZYMO RESEARCH, Orange, CA). DNA in the presence of a 
high salt environment will bind to silica.  The Zymo Clean and Concentrator kit contains 
buffers and microcentrifuge tube inserts containing a silica plug.  Thus, the DNA from 
the specimens can be mixed with a high salt buffer provided with the kit and passed over 
the silica plug in the tube insert by centrifugation thereby binding the DNA to the silica. 
Once bound, contaminants present in an extract can be washed through the silica plug 
using centrifugation leaving clean DNA bound to the silica.  Bound DNA is then eluted 
using 2 X 15ul aliquots of TE-4 (10mM Tris-Cl, pH 8.0 + 0.1 mM EDTA) (warmed to 
65⁰C) with centrifugations between each elution step.  Elimination of the high salt 
environment elutes the DNA from the silica and it collects in the microfuge tube ready 
for amplification.   
VI. Amplification 
A reaction mix was prepared consisting of:  1.25 µl of Q-TAT Primers (SEE 
Table X), 7.5 µl of GoTaq (Promega Corp., Madison, WI), 1.0 µl of patient DNA, 1.0 µl 
of pRL DNA (Promega Corp., Madison, WI) as an internal control, and 1.75 µl of water. 
The samples were amplified in a ABI 9700 thermocycler using the cycling conditions 
described (Allen & Fuller, 2006)and (Wilson, 2006). Briefly, each cycle consisted of 10 
seconds at 98oC, 60 seconds at 55oC, and 30 seconds at 72oC.  After thirty repetitions, the 
thermocycler had a 10 minute 60oC hold time. After the final hold time the thermocycler 
held the specimens indefinitely at room temperature. Once properly amplified, 0.5 µl of 
DNA were then added to a mixture of 24.5 µl of formamide and 0.5 µl of LIZ 500 size 
23 
 
standard. The samples were then placed on the ABI 3130XL Genetic Analyzer (Applied 
Biosystems, Inc., Foster City, CA) to be analyzed.  
VII. Analysis 
 
FIGURE 4. Sample electropherogram 
After sample data had been collected on the ABI 3130XL (FIGURE 4), the area 
RFUs for the Amel X and Amel Y genes were added together and the results were then 
compared to the standard curves to estimate the weight-recovery of cell-free DNA from 
the sample.  The resulting amounts of DNA for the test population was then compared 
with levels of C-reactive protein that accompany them and plotted on a chart. To 
determine if indeed there was a significant correlation, the data was then analyzed using 
different statistical methods. The three comparisons were: 
1. Correlations between CRP and cell-free DNA 
2. Degradation states in the males of the control group as compared to the CRP 
normal and CRP high groups. 
3. Effects of gender on cell-free DNA concentrations. 
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CHAPTER IV 
 
 
RESULTS 
 
 Among the group of samples for which CRP levels were known (n=77) 33 were 
male and 39 were female. DNA from 5 samples was degraded beyond the point where the 
DNA could amplify properly. The lack of amplification in these 5 samples prevented the 
gender typing of these patients based on their cfDNA and was not suitable for further 
analysis. Among the blood donor samples (i.e. “the control group”) (n=37) 24 samples 
were male and 13 were female. One hundred samples were received from MBC, all of 
which contained approximately 100ul of plasma. DNA was only recovered from 37, for 
reasons that are unclear but perhaps relate to how long the donated blood had been stored 
before we received it. Retesting was not possible due to the fact that the specimen was 
used completely.  
Total nuclear DNA (expressed in pg/µl of original plasma) and mtDNA 
(expressed as cell equivalents/µl of original plasma) were quantified and compared 
between the CRP tested samples and the normal controls.  The Satterthwaite modification 
of a t-test was used to transform the data using square roots of the means for the two 
groups. 
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The results indicated a significant difference in cell-free nDNA and mtDNA 
concentrations in the plasma of the Control group vs. the CRP- tested group. (p = 0.0036) 
(Table 3).  
 
Mean nDNA 
(pg/µL) Standard Error 
Standard 
Deviation 
Control Group 1010.6 317.8 1932.9 
CRP Group 22.2875 5.3223 46.7032 
Table 3.  Comparison of cell free nDNA levels in plasma in normal controls and in 
samples subjected to CRP testing The t-test performed using the Satterthwaite 
method on the square root transformation, produced a p value < 0.0001. (Statistical 
analysis performed by Dr. Mark Payton.)  
 
The plasma samples from the control group showed a significantly broader range 
of cell free nDNA values than did those of the CRP test group. Cell free DNA recovered 
from the control group ranged from 79.35pg/µl of nDNA to over 10,000 pg/µl, greater 
than a one hundredfold change in concentration. Recoveries of cell free DNA from the 
CRP test group ranged from 0 pg/µl to 297 pg/µl; the highest cell-free nDNA amount in 
the CRP samples was only about 3 fold more than the lowest of the control group 
samples. While the range of concentrations of cell free nDNA in the two groups overlaps 
there are clear differences between them as shown in Table 3 above. The CRP test group 
was also divided into patients with low levels of CRP (CRP ≤ 1) and patients with high 
CRP levels indicative of inflammation (CRP >1). Cell-free nDNA levels were compared 
between the low and high CRP groups and results are summarized in Table 4. 
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 Mean nDNA (pg/µL) Standard Error 
Low CRP ( ≤ 1) 13.3353 4.7798 
High CRP ( >1) 29.3660 8.6541 
Table 4. Comparison of cell free nDNA levels in plasma with low CRP levels and 
those with high CRP levels. The t-test performed using the Satterthwaite method on 
the square root transformation, produced a p = 0.1129. (Statistical analysis 
performed by Dr. Mark Payton 
 
There was a correlation observed between cell-free nDNA levels and the amount 
of CRP present in samples (r = 0.32635, p = 0.0038). The difference in the p values 
shown for the correlation vs. the value shown in Table 4 can be explained by the fact that 
the correlation is a gradual one across the CRP test group as a whole. This correlation 
also exists for levels of cell-free mtDNA and levels of CRP (r = 0.28366, p= 0.0124) 
(Table 6). These results indicate that as the level of CRP increases so does the amount of 
cell-free DNA (either nDNA or mtDNA). 
 
 
Mean mtDNA 
(CE/µL) Standard Error 
Standard 
Deviation 
Control Group 21.5769 6.5275 39.7052 
CRP Group 3.3869 0.9845 8.6387 
Table 5.  Comparison of cell free mtDNA levels in plasma in normal controls and in 
samples subjected to CRP testing the t-test performed using the Satterthwaite 
method and a square root transformation, produced a p value = 0.0004. (Statistical 
analysis performed by Dr. Mark Payton.) 
 
27 
 
As the amount of mtDNA can’t be directly ascertained (in pg/µl), the amount of 
mtDNA was calculated using cellular equivalents (CE) per microliter, as mentioned in 
the Methods Section. The statistical analysis of cell free mtDNA in the blood donors and 
in the samples subjected to CRP testing is shown in Table 5. The CRP group showed 
samples with a range of concentrations from 0 CE/µl to 57.45 CE/µl. The control group 
showed a range almost three times larger than did the CRP test group in terms of 
mtDNA, ranging from 0 CE/µl to 217.2 CE/µl. The ranges of the concentrations are quite 
similar as shown by the standard error and the standard deviation.  
As with the nDNA analysis, mtDNA concentrations were quantified within the 
CRP test group, which was divided into low CRP and high CRP patients as discussed 
previously and results are shown in TABLE 6. The statistical analysis of the data shown 
in Table 6 showed there was a significant difference in the levels of cell-free mtDNA in 
the low CRP and high CRP group (p=0.0232) 
 
 Mean mtDNA (CE/µL) Standard Error 
Low CRP ( ≤ 1) 1.1194 0.4114 
High CRP ( >1) 5.1797 1.6917 
Table 6. Comparison of cell free mtDNA levels in plasma with low CRP levels and 
those with high CRP levels. The t-test performed using the Satterthwaite method on 
the square root transformation, produced a p = 0.0232. (Statistical analysis 
performed by Dr. Mark Payton 
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Degradation 
 As mentioned in the Methods section, the SRY and HPRT amplicons can be used 
to assess the amount of degradation present in both nDNA and mtDNA (VanDegrift, 
2010; Smith 2011).  The ratio of RFU in high versus low molecular weight amplicons 
amplified in Q-TAT, provides an assessment of degradation of the chromosomal DNA 
template.  Degradation of nDNA is deduced from the concentration estimates for nDNA 
calculated using the Amel-X/Y amplicons divided by the concentration estimate for 
nDNA produced using the SRY locus as shown in Figure 5. Since the SRY locus is 
approximately half the size (110 bp) of the Amel X or Y loci (210 and 216 bp) it will 
amplify more readily in partially degraded DNA because of the smaller template 
requirement.  
 
Figure 5. Degradation Ratio Equation 
 
 
Within the normal control group, 24 of the 25 male samples were analyzed for 
degradation (one being omitted because of possible contamination). In the CRP test 
group, nDNA and mtDNA from 28 of the 29 male samples were quantified. One patient 
was omitted from analysis as SRY failed to amplify though Amel Y was clearly present.  
This isolated inconsistent result may be due to a single nucleotide polymorphism in the 
primer binding region that prevents amplification of the SRY template. 
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It should be noted that 5 patients in the CRP test group contained DNA that was 
either below detectable limits or too degraded to amplify. That these samples did not 
contain an inhibitor of PCR was confirmed by the presence of the pRL amplicon in all of 
the amplifications from these samples.   
 Deg. Ratio Mean Std. Error 
Control Group 0.88743 0.09270 
High CRP 1.08214 0.32652 
Low CRP 0.38449 0.09754 
Table 7. The average degradation ratio and standard deviation for the normal and 
high test groups as well as the control. Control group and high CRP group show no 
statistical difference. Low CRP group is significantly different from the other two (p 
vale = 0.05). Statistical analysis performed by Dr. Mark Payton. 
 
 The samples from the control group and the samples from the high CRP group 
show no significant difference in their ratios of fluorescence of high vs. low molecular 
weight Q-TAT amplicons indicating comparable levels of degradation of cf-DNA. The 
samples from the group with low CRP levels, however, showed a significantly higher 
state of cf-DNA degradation than either the control or normal group (p value = 0.05). 
This shows that patients that have lower CRP levels have more degraded nDNA in their 
plasma than do patients with higher CRP levels. 
Degradation of mtDNA could not be statistically evaluated at this time due to the 
fact that the mt97 locus amplifies so readily that it would not produce a reliably linear 
standard curve to estimate the cell equivalents of mtDNA to compare to the mtDNA 
estimates produced by the mt287 standard curve. However, it is possible to compare the 
30 
 
RFU in the two amplicons to get a general idea of how degradation is affecting cell free 
mtDNA. Shown in Figure 6 is a comparison of RFU in mt97 and mt287 amplicons.  
 
FIGURE 6. Comparison graph of the average RFU for the mt97 and mt287loci.  
 
 
Figure 6 suggests that the state of the mtDNA in each group is different. In the 
samples with low CRP levels, mt97 is amplifying at a higher rate than mt287 which 
would be consistent with a higher state of degradation of the mtDNA in the low CRP 
group; consistent with results for nDNA. The samples with high levels of CRP show an 
almost 1:1 ratio between mt97 and mt287 based upon the RFU, indicating that the 
mtDNA present in these samples is largely intact. The control group shows a much 
higher RFU for mt287 than does the mt97 locus, an almost 2:1 ratio which cannot be 
explained at this time. 
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CF-DNA and Gender 
 Gender Ave. Total DNA X+Y Std. Error 
Control Group F 842.74 280.784 
 
M 1120.51 451.579 
High CRP F 28.31 13.001 
 
M 34.06 11.813 
Low CRP F 15.09 8.544 
 
M 12.37 4.120 
Table 8. Average nDNA and standard error for both genders split up by group. 
There was no significant difference in any of the groups, when compared by gender 
(all p values > 0.77). Statistical analysis performed by Dr. Mark Payton.  
 
The sex of the patient doesn’t seem to be a factor that effects the concentration of 
DNA in their plasma, as both males and females show a wide range of different 
concentrations of both nDNA and mtDNA, in the control group as well as the low CRP 
group and the high CRP group. Using ANOVA (Analysis of Variance) and assuming a 
two factor factorial, Table 8 above shows that in all three groupings, males and females 
showed no significant difference in their respective average levels of nDNA. The p 
values for the control group, high CRP group and the low CRP group were, 0.7897, 
0.7781 and 0.9137 respectively.  
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Next a comparison of all three groups was made by looking at the genders 
separately, using the same information from TABLE 6 above and the same ANOVA 
methods (performed by Dr. Mark Payton) mentioned previously in this section. Results 
showed no statistical similarity for males or females separately across the three groups (p 
value < 0.0001). This supports the finding that the three groups (control, low CRP and 
high CRP) have different levels of cfDNA.
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CHAPTER V 
 
 
DISCUSSION 
The purpose of this study was to investigate levels of cfDNA in the plasma of a 
healthy control group compared with a patient population whose inflammation status is 
quantified through the plasma CRP clinical test.  Blood donors represented the initial 
“control group” and were chosen because each donor goes through a health questionnaire 
and is assessed by collection personnel before donating blood.  Results from our study 
however demonstrated that the control group exhibited some of the highest cfDNA levels 
and generally control samples had more cfDNA than any of the CRP samples. In 
addition, there was a very wide distribution of cf-DNA levels in the control group. Thus, 
the blood donor population may not represent a good “control” group for studies such as 
this one. Among all samples there was no difference between males and females and thus 
gender does not appear to be a factor affecting circulating cfDNA. 
Among the samples with known CRP levels, those exceeding the clinical 
threshold (CRP >1) that defines an inflamed state were grouped into the “high CRP” 
group.  The remaining samples falling below the clinical CRP threshold (CRP ≤ 1) were 
the “low CRP” group.  Interestingly, the low CRP (lwCRP) group exhibited a tighter 
range of cfDNA levels for both nDNA and mtDNA levels, and the mean cfDNA was 
significantly lower than among high CRP samples (hCRP) as well as among the controls.   
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An explanation for this phenomenon could be selection bias in our choice of a control 
group.  Since the CRP level of the blood donors was unknown, it is possible that 
individuals within this group could have wide ranging CRP levels on the day of donation.  
If the inflammation were not debilitating to the individual, they could still probably 
donate.  In contrast, the samples in the low CRP group were specifically selected based 
upon low, sub-pathologic levels of CRP and thus, if there were a correlation between 
cfDNA and CRP, that relationship would be apparent in this group.   
Using the Q-TAT method, cell free nDNA and mtDNA were quantified in the 
same PCR reaction. Once DNA amounts in all the samples were estimated, the 
concentrations were compared using statistical analysis. The amount of cell-free nDNA 
and mtDNA showed no correlation between the control group and the CRP test group 
A correlation between cf-DNA, both nDNA and mtDNA, and the levels of CRP 
present in the test group was observed. This can be explained by CRPs role in the body. 
As mentioned previously, CRP not only reacts with phosphocholine in damaged cell 
membranes but it is also recognized by molecules of the complement pathway which act 
primarily to destroy foreign cells (bacteria and fungi) but will also destroy damaged and 
apoptotic cells. This could cause more DNA to be liberated from cells. Due to CRPs role 
in destroying damaged and apoptotic cells, the physical state of the cf-DNA was 
analyzed. As the CRP and compliment pathway destroy cells, DNA can be liberated more 
quickly, however the DNA that is liberated from the cell may not remain intact due to the 
presence of DNase and other materials in human plasma that degrade DNA. The nature 
of cell free DNA was characterized in one study as being between 180-10,000 bps in 
length (Van Der Vaart & Pretorius, 2008). Thus, cfDNA may exist in varying states of 
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degradation. The Q-TAT assay was used to assess degradation in our samples.  The ratio 
of the estimate of pg of nDNA recovered from a sample and estimated using SRY versus 
the estimate calculated using Amel-X/Y was used to quantify degradation (Smith 2011).  
The Amel X/Y locus is approximately twice the size of the SRY locus. In intact DNA the 
ratio should be approximately 1:1. The control group and the high CRP group showed no 
statistical difference in the estimated level of nDNA degradation, while the test group 
with clinically low/normal levels of CRP was significantly different from the other 
groups and exhibited a greater proportion of degraded DNA. This analysis showed that 
patients with little to no inflammation have a higher level of degraded cf-DNA than do 
patients with higher levels of inflammation. This result was somewhat unexpected but 
may reflect a difference in the balance between cellular destruction (greater in the high 
CRP group) versus DNA degradation (occurring at equal rates in high and low CRP 
groups).  
Expanding the usefulness of cfDNA 
 For years it has been known that DNA is present in human plasma free from the 
cells where it originates. The how and the why of cell-free DNA in plasma has been a 
source of much debate. The fact that it is present in plasma of all humans and quite often 
is present in elevated concentrations in patients with certain health conditions, ranging 
from cancer to pregnancy, means that it can be used as a minimally invasive qualitative 
test. It is possible that testing for cell-free DNA may become ‘an important and integral 
aspect of routine molecular testing,(Butt, 2008)’. 
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 C - reactive protein is the most common marker used by doctors to diagnose the 
presence of inflammation. The problem with CRP is that it is not a very specific marker; 
it rises due to many different kinds of inflammation from sepsis to heart attacks. Thus 
selecting our groups for quantitation of cf-DNA may have been based on a somewhat 
non-specific marker of inflammation. CRP’s role in the body is that it helps to activate 
the compliment pathway to eliminate foreign bodies, damaged cells and apoptotic cells.  
Two studies mentioned earlier performed by Fatouros et al. 2006 and by Moreira 
et al. 2010 focus on the use of cell free DNA and how it compares to currently accepted 
methods of measuring inflammation. The Fatouros et al. 2006 study concluded that in 
regards to intense training cell-free DNA was a much better indicator of overtraining than 
was CRP. Cell free DNA increased dramatically during periods of intense training where 
CRP and other methods took longer to elevate. When comparing cf DNA and CRP for 
any correlation Fatouros et al. concluded that there wasn’t any. The results contrast our 
own in that we did show a correlation. However, in the two studies the reasons for the 
elevated CRP levels were quite different which could explain the difference. 
The Moreira et al. 2010 study showed that similarly cell-free DNA was a better 
indicator of sepsis and septic shock than was CRP. The levels of cf DNA increased 
dramatically, ‘10-fold the upper limit of the reference range’ (Moreira, et al., 2010) when 
comparing normal healthy patients to patients suffering from septic shock. Interestingly, 
Moreira et al. noticed a slight correlation between cfDNA, CRP and other tests. The 
authors do note however that similar studies have been done, some showing correlation 
between CRP and cfDNA and others showing that no such correlation exists. 
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Areas for further Study 
 The goal of all clinical testing is to develop tests that are more accurate, require 
less sample volume and are cost effective. Cell-free DNA is widely associated with 
several known health states that are monitored clinically. While this study has shown 
only a small negative correlation between cfDNA and inflammation, there are many other 
diseases that there has been no research done about the concentration of cfDNA. If more 
information was available for various diseases it might be possible that cfDNA could be 
used as a more efficient clinical test for these diseases. Once the concentration of cf-DNA 
was established certain disease states could be eliminated. As well, the remaining cleaned 
DNA could be used with other molecular targets to further the diagnosis.       
Conclusion 
 The analysis of cf-DNA is an area of study with many clinical uses. The goal of 
this study was to identify the relationship, if any between cf-DNA and levels of 
inflammation as determined by CRP levels. Even though the control group proved not to 
be the optimal choice for baseline cf-DNA levels, due to wide fluxuations in cf-DNA 
concentrations and unknown levels of CRP, useful analysis could still be performed 
within the CRP known group by splitting up the patients with clinically low CRP from 
those with clinically high CRP.  A correlation was found between CRP and cf-DNA 
levels, meaning as the CRP level rises so does the level of cf-DNA. In addition the low 
CRP group exhibited more degraded cf-DNA than did the high CRP group or the control 
group. Lastly, gender doesn’t appear to affect the concentration of cf-DNA. 
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Scope and Method of Study:  
The presence of DNA in the plasma of humans has been known since 1948. The 
pathway that leads to the liberation of DNA from the cell still remains open to debate. . 
Scientists have proposed the following mechanisms underlying the presence of cell-free 
DNA in plasma: apoptosis, necrosis, terminal differentiation and active secretion. While 
the exact method of DNA liberation is still unclear, the usefulness of cell-free DNA for 
diagnostic purposes has not remained in question. The purpose of this study was to 
determine the link, if any, between the levels of cell-free DNA in patient plasma and their 
level of inflammation.  By measuring the levels of cell-free DNA in healthy patients and 
patients with elevated levels of C-reactive protein, which is known to be elevated in 
inflammation, any link between the concentration of cell-free DNA in patient plasma and 
the level of inflammation could be investigated. 
Findings and Conclusions:   
 Using the Q-TAT method of quantitation, nDNA and mtDNA were quantitated 
simultaneously. The results indicated a significant difference in cell-free nDNA and 
mtDNA concentrations in the plasma of the control and test groups (p = 0.0036). There 
was a slight correlation observed between cell-free nDNA and the amount of CRP 
present in samples, possibly explained by the role CRP plays in the complement pathway, 
destroying foreign bodies and damaged cells. The samples from the group with low CRP 
levels showed a significantly lower ratio of degradation than either the control or normal 
group (p value = 0.05). This shows that patients that have lower CRP have more 
degraded nDNA in their plasma than do patients with higher CRP levels. Gender didn’t 
affect the concentration of nDNA or mtDNA in any of the groups. 
  
 
